share_log

Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8

坎托·菲茨杰拉德以增持评级启动对Capricor Therapeutics的报道,宣布目标股价为8美元
Benzinga ·  01/05 10:31

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Overweight rating and announces Price Target of $8.

坎托·菲茨杰拉德分析师克里斯汀·克鲁斯卡以增持评级开始对Capricor Therapeutics(纳斯达克股票代码:CAPR)进行报道,并宣布目标股价为8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发